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Abstract To evaluate perceived pain during repetitive
annual endometrial sampling at gynaecologic surveillance
in asymptomatic women with Lynch syndrome (LS) over
time and in addition to symptomatic women without LS,
undergoing single endometrial sampling. In this prospec-
tive study, 52 women with LS or first degree relatives who
underwent repetitive annual gynaecological surveillance
including endometrial sampling of which 33 were evalu-
ated twice or more and 50 symptomatic women without LS
who had single endometrial sampling, were included. Pain
intensity was registered with VAS scores. Differences in
pain intensities between subsequent visits (in LS) and
between the two groups were evaluated. The use of pain-
killers before endometrial sampling was registered. If
women with LS decided for preventive surgery, the reason
was recorded. The LS group reported a median VAS score
of 5.0 (range 0–10) at the first surveillance (n = 52) and at
the second visit (n = 24). Women who repeatedly under-
went endometrial sampling more often used painkillers for
this procedure. During the study period 7/52 (13 %)
women with LS choose for preventive surgery, another
4/52 (8 %) refused further endometrial sampling. Painful
endometrial sampling was mentioned as main reason to
quit screening. The median VAS score of the 50 symp-
tomatic women was 5.0 (range 1–9). Endometrial sam-
pling, irrespective of indication, is a painful procedure,
with a median VAS score of 5.0. During subsequent pro-
cedures in women with LS, the median pain score does not
aggravate although one in five women chose an alternative
for endometrial sampling.
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Introduction
Women with Lynch syndrome (LS) have a significantly
increased risk of endometrial cancer (25–70 %) depending
on the type of gene mutation [1–6]. Currently there is
evidence to support the efficacy of surveillance for the
early detection of endometrial cancer in women with LS
[1, 7–9]. The main goal of surveillance for endometrial
cancer in LS is the detection of endometrial cancer at an
early or premalignant stage and to provide early treatment
with improved prognosis [10]. Data about effectiveness of
annual gynaecological surveillance in women with LS or
first-degree relatives at 50 % risk of LS who underwent
surveillance in our hospital between 1991–2002 [11] and
2003–2012 [12] have been published before. Both studies
concluded that surveillance with endometrial sampling is
effective in the detection of (pre)malignant endometrial
lesions in women with LS.
However, since gynaecological surveillance by
transvaginal ultrasonography was extended by standard
endometrial sampling, the clinical impression was that
women more often complained about the painfulness of
surveillance, that this deteriorated over time, and that this
was associated with fear for the procedure and even opting
out. Besides, the clinical impression was that LS women
who came for annual surveillance more often reported
intense pain during endometrial sampling than symp-
tomatic women who had single endometrial sampling for
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bleeding problems (personal observation). For that we
hypothesised that pain increases during subsequent
endometrial samplings in women with LS.
The aim of this study was to evaluate the intensity and
impact of pain during repetitive annual gynaecologic
surveillance in women with LS or first-degree relatives at
50 % risk of LS. Pain scores of LS women were evaluated
over time, and it was analysed if fear for endometrial
sampling was a motivator to decide for preventive surgery
or to stop the surveillance visits in women with LS. In
addition, the pain scores were compared to pain scores of
symptomatic women without LS who underwent single
endometrial sampling for diagnostic reasons.
Methods
Between January 2011–December 2015 women with LS
(carrier of a pathogenic mutation in either MLH1,MSH2,
MSH6, Epcam or PMS2) or first-degree relatives at 50 %
risk of carrying a LS mutation were seen in the Family
Cancer Clinic of the University Medical Center and a
regional hospital (Martini Hospital) in Groningen, The
Netherlands. All first degree relatives at 50 % risk of car-
rying a gene mutation were offered genetic testing and
those (nine) women not willing to undergo that (yet), were
also included in this study. All women were offered annual
gynaecological surveillance by transvaginal ultrasound,
endometrial sampling (Pipelle) with measurement of the
VAS score and serum CA125 measurement according to
the Dutch National Guideline [13]. Data about endometrial
samplings of some of these women have been described
earlier in a study about the additional value of endometrial
surveillance in women with LS [12].
The symptomatic non-Lynch women were seen in the
outpatient clinic of the regional hospital in Groningen
between January 2014 and August 2014. They underwent
single endometrial sampling for diagnostic reasons. If
women used daily painkillers they were excluded from the
study. Written informed consent was obtained from all
patients in this study. The ethics committee of the Martini
Hospital in Groningen approved the study. All relevant
data were entered into a separate password protected
database, and protection of a patient’s identity was guar-
anteed by assigning study specific unique patient numbers.
Measurements of outcomes
Pain measurement during endometrial sampling was eval-
uated at the surveillance visit with the Visual Analogue
Scale (VAS score, range 0–10). Before endometrial sam-
pling was performed, all women received information
about the VAS score. They were instructed to give the pain
score by using a VAS measuring staff (0 is no pain, 10 is
the most severe pain you can imagine) directly after the
endometrial sampling. At every surveillance visit it was
documented if women with LS used painkillers before the
endometrial sampling or if they declined further surveil-
lance, and if so, for what reason.
Data collection
For each woman, patient characteristics and clinical data
including the medical history, use of daily (pain) medica-
tion, nulli- or multiparity, the age at the first surveillance,
number of previous endometrial samplings, menopausal
status, symptoms, results of TVU’s and of the endometrial
sampling, pathology reports, CA 125 levels, pain mea-
surement by VAS scores, treatment after endometrial
abnormalities, decision for preventive surgery and the
motivation for preventive surgery were collected.
Power analysis
To analyse a VAS score difference of 1 point between
annual surveillance in the Lynch group and single
surveillance in the symptomatic group, with a standard
deviation of 2.0, alfa of 0.05 and a power of 80 %, two
groups of 49 women each were needed.
Data analysis
Characteristics of women with LS or first-degree relatives
at 50 % risk and of the symptomatic group and their dis-
ease were described. The LS group and in addition to
symptomatic women without LS were analysed on the
outcome parameters: VAS scores, the use of painkillers
before endometrial sampling, and in the LS group the
decision to decline further surveillance. Differences
between VAS scores over time were analysed for those
women with LS or first-degree relatives at 50 % risk,
having two visits. Then potential determinants (menopau-
sal status, nulli/multiparity, and having a history with
surveillance) were evaluated on our outcomes. This was
done by Mann–Whitney U testing (in case of VAS scores)
or Chi square testing (in case of use of painkillers and
decision for preventive surgery). If women decided for
preventive surgery, the reason was described. Data analysis
was performed with SPSS statistics version 20.
Results
In the women with LS group (n = 52), 97 annual gynae-
cological surveillances by TVU and endometrial sampling
with VAS scores were performed. The mean age of the
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women at the first visit in this study period is 45 (range
33–69) years. A total of 33/52 LS women underwent
subsequent endometrial surveillance after 1 year and in
24/33 endometrial samplings were performed (Table 1).
The symptomatic group (n = 50) had a mean age of 59
(range 40–82) years (Table 1). In this latter group the
indication for endometrial sampling was postmenopausal
bleeding (n = 33; 66 %), irregular vaginal bleeding
(n = 6; 12 %), menorrhagia (n = 7, 14 %) and other
indications (n = 4; 8 %).
In the LS group, the median VAS score of the endome-
trial sampling at the first visit in this study period was 5.0
(range 0–10), see Table 2. The median VAS score at the
second visit was also 5.0 (range 0–10). No women in the LS
group used daily painkillers, 11/52 used painkillers
(NSAID’s) 1–2 h before the endometrial sampling due to
severe pain at previous visits. In the LS group, post-
menopausal women (n = 12) reported a median VAS score
of 6.5 (range 3–10) compared to premenopausal women
(n = 40) who reported a VAS score of 5.0 (range 0–10) at
the first surveillance visit (Table 3). In 11/52 nulliparous
women, the median VAS score was 6.0 (range 2–9), com-
pared to 5.0 (range 1–10) in 36 multiparous women.
Women who started surveillance before 2011 reported the
same median VAS score of 5.0 than women who started
surveillance between 2011 and 2015, although they more
often used painkillers (Table 3). In Fig. 1 is shown that
most women report a substantial VAS score, which was
highly individual with a wide range (0–10). The first and the
second VAS score of the same women were comparable.
In the LS group five women stopped surveillance at the
second surveillance visit and choose for preventive surgery
and four women decided for preventive surgery at the third
surveillance visit in this study period. In total 9/52 women
(age 39–48 years, mean 44 years) underwent preventive
surgery and 7/9 of these women reported pain during the
endometrial sampling, besides fear for cancer, as the main
reason to decide for preventive surgery. These nine women
were informed about the option to get preventive surgery or
to continue annual surveillance with a good counselling
about the risks and the benefits of both procedures. All nine
women who choose for preventive surgery had endometrial
sampling before the operation with a median time between
the endometrial sampling and the preventive surgery of
10 months (range 3–24 months). None of the women
reported complaints of irregular blood loss. Four (8 %)
women in the LS group refused one or more endometrial
samplings because of fear for pain. One woman denied
further surveillance after two painful endometrial sampling
procedures (VAS 9 and 10).
Of nine women who choose for preventive surgery, the
pathology report of endometrial tissue was normal in all
women. The pathology report of 7/9 (78 %) women
showed normal ovaries, one benign ovarian cyst was found
and one patient was diagnosed with an unexpected FIGO
stage IA, grade 1 intestinal ovarian adenocarcinoma within
a teratoma. In this patient, at the last surveillance visit
3 months prior to the operation, a unilocular mass at the
right ovary of 8.5 9 6 cm was seen with a normal aspect of
the other ovary and absence of ascites. The level of CA 125
Table 1 Characteristics of patients and endometrial sampling










LS* (N = 17)
Fourth
surveillance
LS* (N = 5)
Fifth
surveillance
LS* (N = 3)
First visit
(N = 50)
Mean age (range) 45.1 (33–69) 46.4 (34–70) 46.2 (35–71) 50.4 (40–66) 53.2 (41–67) 59.4 (40–82)
Menopausal status
Premenopausal 40 (77 %) 26 (79 %) 13 (76 %) 3 (60 %) 2 (67 %) 12 (24 %)
Postmenopausal 12 (23 %) 7 (21 %) 4 (24 %) 2 (40 %) 1 (33 %) 38 (76 %)
Number of children
Nulliparous 11 (21 %) 8 (24 %) 4 (24 %) 1 (20 %) 1 (33 %) 2 (4 %)
Primi/multiparous 36 (69 %) 21 (64 %) 11 (65 %) 3 (60 %) 1 (33 %) 33 (66 %)
Unknown 5 (10 %) 4 (12 %) 2 (11 %) 1 (20 %) 1 (33 %) 15 (30 %)
Started surveillance with
endometrial sampling before the
study period
28 (54 %) 21 (64 %) 13 (76 %) 5 (100 %) 3 (100 %) NA
* First surveillance with endometrial sampling and VAS score, 28 (54%) women have had more surveillance visits with endometrial sampling
before this study period
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at that moment was 34 kU/L (Risk of Malignancy Index:
34) [14].
The median VAS score in the symptomatic group was
5.0 (range 1–9) (Table 2). None of them used painkillers
daily or before the endometrial sampling. These symp-
tomatic women reported a median VAS score of 4.0 (range
1–8) in the 12 premenopausal, and 5.0 (range 1–9) in the 38
postmenopausal women. Two women were nulliparous and
reported a median VAS score of 3.0 and in 33 multiparous
women the median VAS score was 4.5 (range 1–8). Of 15
women the obstetrical history was unknown (median VAS
score 5.0 (range 2–9).
Discussion
Endometrial sampling, irrespective of indication, is a
painful procedure, with a median VAS score of 5.0 in
asymptomatic women with LS and in women with abnor-
mal bleeding. We observed no progressive pain scores in
subsequent procedures in the group women with LS. Of 52
women in the LS group, 7 (13 %) decided for preventive
surgery and gave pain at the annual surveillance besides of
fear for cancer, as an important reason for the preventive
surgery. LS women reported no more pain during annual
endometrial sampling than the symptomatic women with-
out LS who underwent single endometrial sampling,
although a substantial proportion of these LS women (11/
52) used painkillers during subsequent endometrial
samplings.
This is the first study that describes the level of pain
during endometrial sampling in asymptomatic and symp-
tomatic women and the influence of pain scores on clinical
decision making during annual surveillance in women with
LS. A limitation of this study is the small number of
patients analysed because LS is not a very common trait.
In the last decades more LS families are detected and
more annual gynaecologic surveillance procedures are
performed in these women. In literature, the effectiveness
of surveillance in women with LS and the role of
Table 2 Outcomes of VAS scores of endometrial sampling in women with LS and symptomatic women


























Median VAS score (range) 5.0 (0–10) 5.0 (0–10) 6.0 (1–9) 7.0 (4–7) 7.0 (1–9) 5.0 (1–9)
Used painkillers before endometrial sampling 11 (21 %) 9 (38 %) 5 (38 %) 4 (80 %) 2 (67 %) 0
Endometrial sampling 52 (100 %) 24 (73 %) 13 (76 %) 5 (100 %) 3 (100 %) 50 (100 %)
No endometrial sampling
Only TVE during surveillance 0 4 0 0 0 0
Decided for preventive surgery 0 5 4 0 0 0




P value Used painkillers before first
surveillance visit during study
period (n = 11/52) (21 %)
P value Decision for
preventive surgery
(n = 9) (17 %)
P value
Menopausal status
Premenopausal (n = 40) 4.0 (0–10) 0.78* 8/40 (20 %) 0.14* 9/40 (23 %) 0.07*
Postmenopausal (n = 12) 6.5 (3–10) 3/12 (25 %) 0/12
Number of children
Nulliparous (n = 11) 6.0 (2–9) 0.39* 4/11 (36 %) 0.16* 1/11 (9 %) 0.34*
Primi/multiparous (n = 36) 4.0 (1–10) 5/36 (4 %) 8/36 (22 %)
Unknown (n = 5) 8.0 (3–10) 2/5 (40 %) 0/5
Start surveillance
Before 2011 (n = 28) 5.0 (0–10) 0.97* 10/28 (36 %) 0.04 4/28 (14 %) 0.62*
After 2011 (n = 24) 5.0 (2–10) 1/24 (4 %) 5/24 (21 %)
* Non significant
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preventive surgery have been described before. However,
as far as we know, there is no information about the degree
of pain as well as the influence of pain scores on clinical
decision-making during surveillance in women with LS.
Only one study reported on patient acceptability of
endometrial sampling in LS surveillance and the authors
conclude that transvaginal ultrasonography is associated
with less discomfort than hysteroscopy or endometrial
sampling, and will therefore be the preferred test of choice
for the majority [15]. There is no significant difference
between the pain scores for hysteroscopy and endometrial
sampling [15]. In studies reporting on preventive surgery in
women with LS no information is given so far about the
influence of pain during the surveillance visits in making
the decision for preventive surgery [16, 17]. Main outcome
of this study was pain during the endometrial sampling,
although there are a lot of factors that should be considered
by physicians in making surveillance decisions with their
patients. This includes, beside the level of pain and
inconvenience, fear for cancer, having to come to the
hospital, travel opportunities, the risks and benefits of
surgery, child bearing wish and the costs of the surveillance
versus preventive surgery. In this study we focussed on the
pain because we had the impression that women who
underwent repetitive annual endometrial sampling reported
more pain than symptomatic non-LS women who got sin-
gle endometrial sampling. Because women with LS
undergo colon surveillance as well, we searched for liter-
ature about pain scores during surveillance for colon can-
cer. Nebgen et al. [18] described combined endometrial
sampling and colonoscopy in 55 women with LS under
conscious sedation and concluded that this combination of
surveillance is a less painful experience in women with LS
than endometrial sampling in an office setting without
sedation. Huang et al. also described combined surveil-
lance by endometrial sampling and colonoscopy under
conscious sedation in 42 women with LS of whom 19
women had a previous endometrial sampling in the office
setting. These women reported significantly lower pain
levels in the combined procedure compared to the previous
office procedure without sedation [19]. In this study 11/52
(21 %) LS women used painkillers (NSAID’s) before the
endometrial sampling was performed, due to painful
experiences during previous procedures. In the randomised
controlled trial of Somchit et al. [20] women showed a
significantly reduced pain score during the endometrial
sampling in the group who used an NSAID compared to
the group who used placebo. In our study, there were no
statistically significant differences between post-
menopausal and nulliparous women in the reported median
VAS scores as compared to premenopausal and multi-
parous women. We expected a difference, as it might be
that the endocervix is less easy to pass in postmenopausal
and nulliparous women what might contribute to a higher
level of pain during the procedure. In this study, 11 women
used painkillers before the subsequent endometrial sam-
pling because of a painful procedure during the last
surveillance visit (VAS 7–10). These 11 women were
almost all (8/11) premenopausal and only four of 11
women were nulliparous.
In this study nine women choose for preventive surgery,
mostly because of fear for pain. All had normal findings
and were a-symptomatic since the last surveillance, per-
formed 10 (3–24) months before surgery. They did not
undergo endometrial sampling shortly before the preven-
tive surgery. Although there are no recommendations for
endometrial sampling prior to risk reducing surgery in
women with Lynch syndrome, some authors report on
occult endometrial cancers in women with Lynch syn-
drome [1, 21] and others report only symptomatic
endometrial cancers found by complaints and/or thick
endometrial response on transvaginal ultrasound [12, 22].
In this study none of the nine pathology reports of the
women who choose for preventive surgery showed a
(pre)malignancy of the endometrial tissue. In conclusion,
irrespective of the indication, women report substantial
pain scores during repetitive and single endometrial sam-
pling, although pain scores differ substantially between
individuals. In this study it could not be confirmed that pain
increases during subsequent endometrial samplings in
women with LS. A substantial proportion (13 %) of these
women decided for preventive surgery and gave pain at
annual surveillance, besides fear for cancer, as a major
reason for this decision. We suggest that more attention is
needed for the impact of pain during endometrial sampling
Fig. 1 Level of VAS scores of the first and second visit among
women with LS or first degree relatives (n = 24)
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and use of painkillers should be encouraged (NSAID’s).
Other less painful methods such as combining with colo-
noscopy under conscious sedation [18, 19], liquid biopsies
in blood [23] and analysing endometrial tissue to detect
endometrial cancer by tampons [24] should be explored to
omit painful repetitive endometrial sampling in women
with LS.
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